Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Upcoming plasma biomarkers for Alzheimer’s disease: Aβ, p-tau and GFAP

Pamela Lukasewicz Ferreira • 16 Mar 2022
AD/PD 2022
Alzheimer’s Disease

Pamela Lukasewicz Ferreira, PhD, University of Pittsburgh, Pittsburgh, PA, provides an overview of the different Alzheimer’s disease biomarkers. Amyloid-beta (Aβ) is an established biomarker used in CSF lumbar puncture, but when used in blood, it is not very consistent. p-tau-217, p-tau-181, and p-tau-231 are the closest biomarkers to be used in a clinical setting, as a robust method has been identified which can predict Alzheimer’s disease with high accuracy. Glial fibrillary acidic protein (GFAP) requires more research as it is not specific to Alzheimer’s disease; it will be most useful when used in combination with other biomarkers. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.

More from Pamela Lukasewicz Ferreira

The impact of plasma p-tau217: pre-screening and selecting participants for AD trials
2:19
The impact of plasma p-tau217: pre-screening and selecting participants for AD trials
Pamela Lukasewicz Ferreira • 13 Jul 2026
Head-to-head comparison of the association of flortaucipir and MK6240 with plasma p-tau217 in AD
1:14
Head-to-head comparison of the association of flortaucipir and MK6240 with plasma p-tau217 in AD
Pamela Lukasewicz Ferreira • 13 Jul 2026
Cost-efficiency and feasibility of using plasma p-tau217 as a prescreening method in AD trials
2:05
Cost-efficiency and feasibility of using plasma p-tau217 as a prescreening method in AD trials
Pamela Lukasewicz Ferreira • 13 Jul 2026
Evolving use of tau-specific fluid biomarkers for Alzheimer's disease
1:15
Evolving use of tau-specific fluid biomarkers for Alzheimer's disease
Pamela Lukasewicz Ferreira • 8 Mar 2024

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
MenoCog: risk and protective factors for cognitive function in the menopause transition
2:37
MenoCog: risk and protective factors for cognitive function in the menopause transition
Amber Watts • 14 Jul 2026
What are the biological mechanisms underlying the higher prevalence of AD in women?
1:55
What are the biological mechanisms underlying the higher prevalence of AD in women?
Amber Watts • 14 Jul 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals